Genovis switches to pure direct sales of all products in the US

Genovis is switching to direct sales in the US in 2014 and as of today full
customer support is available during US business hours. The company is
represented in the US by John M. Lindsay, VP of Sales and Marketing North
America and Philip Onigman, Director of Technical Marketing.
“Our products are unique and have gained acceptance in the market over the past
two years, so it is strategically important to have a presence and maintain
direct relationships with key customers and Key Opinion Leaders (KOL). The
distributors have been an asset to Genovis in the initial commercialization
phase. The transition to direct sales will enable us to make better use of our
resources and be more effective in the sales process, which benefits both
Genovis and our customers,” says Sarah Fredriksson, CEO Genovis.

US office

Genovis AB

245 First Street

Cambridge, MA 02142

T: +1(617)444-8421
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00